That’s nearly 1 in 32
Colorectal cancer screening that’s built for both high sensitivity and high compliance.
high sensitivity + high compliance
92% sensitivity in detecting colorectal cancers, stages I-IV*5
87% specificity overall, excluding colorectal cancer and advanced adenomas‡5
68% compliance with Cologuard†
88% of patients were “very satisfied” or “satisfied” with their testing experience6
*Cologuard sensitivity, per stage of cancer: I: 90% (n = 29); II: 100% (n = 21); III: 90% (n = 10); IV: 75% (n = 4).4
†Internal data. Exact Sciences Laboratories. Cologuard's compliance rate represents the cumulative completed tests from kits shipped to patients during the six-month period ending 12 months prior to the end of the most recent quarter reported, excluding program orders.
‡Cologuard specificity: 87% overall specificity excluding colorectal cancer and advanced adenoma; and including all nonadvanced adenomas, non-neoplastic findings, and negative results on colonoscopy. 90% specificity in participants with no lesions biopsied on colonoscopy.4
REFERENCES 1. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. Apr 9 2012;172(7):575-582. 2. Quick Facts Colorectal Cancer Screening in U.S. Behavioral Risk Factor Surveillance System – 2016. Centers for Disease Control and Prevention website. Accessed August 15, 2018. 3. Annual Estimates of the Resident Population by Single Year of Age and Sex for the United States: April 1, 2010 to July 1, 2017. United States Census Bureau website. Accessed August 14, 2018. 4. American Cancer Society. Cancer Facts & Figures 2017. American Cancer Society website. Accessed August 14, 2018. 5. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-1297. 6. Internal data. Exact Sciences Laboratories. Cologuard's patient satisfaction rate from launch to date. August 2018.